Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Dov Bergwerk Receives 9,433 RSUs at Teva Pharmaceutical

Dov Bergwerk, Interim Chief Legal Officer of Teva Pharmaceutical Industries Ltd., filed a Form 4 on November 12, 2026, reporting the acquisition of 9,433 restricted share units on November 10, 2026.

Manish Choudhary | 12 November 2026

Mark Sabag Exercises and Sells 44,710 Teva Shares

Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd., filed a Form 4 on November 12, 2026, reporting the exercise of stock options and the same-day sale of 44,710 ordinary shares.

Vinay Lochav | 12 November 2026

Teva CEO Francis Sells 250,000 Shares on Nov 10

Richard D. Francis, President and CEO of Teva Pharmaceutical Industries Ltd., filed a Form 4 on November 12, 2026, reporting the sale of 250,000 ordinary shares on November 10, 2026, pursuant to a Rule 10b5-1 trading plan.

Aditi Sarkar | 12 November 2026

David J. Brailer Files Initial Ownership Statement at Teva

Director David J. Brailer filed a Form 3 initial statement of beneficial ownership with the SEC on November 12, 2026, reporting his status as a newly affiliated director of Teva Pharmaceutical Industries Ltd. as of November 3, 2026.

Aakashdeep | 12 November 2026

Kozarich Proposes 500-Share LGND Sale via UBS, Nov 2026

Director John W. Kozarich of Ligand Pharmaceuticals Inc filed a Form 144 notice on November 12, 2026, proposing the sale of 500 shares of Ligand common stock through UBS Financial Services, Inc., with an approximate sale date of November 12, 2026.

Vinay Lochav | 12 November 2026

Teva's Sabag Files to Sell 44,710 Shares via Option Exercise

Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd, filed a Form 144 notice on November 12, 2026, proposing the sale of 44,710 ordinary shares acquired through a stock option exercise and sale on the same date.

Shwetambri Chauhan | 12 November 2026

Keros Director Anne Prener Plans Sale of 574 RSU Shares

Director Anne Prener of Keros Therapeutics, Inc. filed a Form 144 notice on November 12, 2026, disclosing a proposed sale of 574 shares of common stock acquired through RSU vesting, with an aggregate market value of $5,619.00.

Manish Choudhary | 12 November 2026

Innovex Officer Reed Kendal Plans Sale of 20,868 Shares

Innovex International, Inc. officer Reed Kendal filed a Form 144 notice of proposed sale of 20,868 shares of common stock on November 12, 2026, pursuant to Rule 144 under the Securities Act of 1933.

Manish Choudhary | 12 November 2026

Alphabet Director Hennessy Files to Sell 300 Class A Shares

Alphabet Inc. director John L. Hennessy filed a Form 144 notice of proposed sale of 300 Class A Common shares on November 12, 2026, with UBS Financial Services, Inc. acting as broker on the Nasdaq exchange.

Aakashdeep | 12 November 2026

Accel Entertainment Officer Kozlik Plans 3,600-Share Sale

Christen Kozlik, an officer of Acel Entertainment, Inc., filed a Form 144 notice of proposed sale on November 12, 2026, disclosing plans to sell 3,600 shares of the company's common stock on the New York Stock Exchange.

Anjali Anand | 12 November 2026
Support

Hi! How can we help you today?

Loading…